Clinical trials
Esophageal Carcinoma clinical trials
Below are recruiting esophageal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06971848Recruiting
Skin testing for biologic drug allergies
This trial checks if people can safely receive certain biologic drugs without allergic reactions, using skin tests to see how the body reacts. It may help find out if you are allergic to a biologic medicine you have taken before.
AngersAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT05043688RecruitingPhase 3
Camrelizumab with chemo before surgery versus chemo-radiation
This Phase 3 trial compares two ways of treating resectable esophageal squamous cell cancer: (1) camrelizumab plus chemotherapy before surgery versus (2) chemo-radiation. It aims to see whether adding camrelizumab before surgery can improve outcomes for people who are planned to have their tumor surgically removed.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06475196Enrolling by invitation
Immunotherapy plus chemo before surgery for esophageal cancer
This trial tests a combination of immunotherapy (sintilimab) and chemotherapy given before surgery for esophageal cancer that can be surgically removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT07627347Recruiting
Anlotinib and Bemocizumab for Early Esophageal Cancer
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06698692Recruiting
Preventing low blood counts with trilaciclib after chemoradiation for esophageal cancer
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
Nanjing, JiangsuAges 18 years+ - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT07430579Recruiting
Adebrelimab with chemo for esophageal cancer
This trial tests adding adebrelimab (an immunotherapy drug) to standard chemotherapy for people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination helps shrink tumors before surgery.
JinanAges 18–80 - NCT03734952Recruiting
Radiation after esophagus surgery for stage II–III cancer
This study looks at whether giving radiation after surgery (after chemo and radiation before surgery) can improve outcomes for people with squamous cell esophagus cancer in the chest. You may be considered if you are well enough for treatment and your cancer has not spread.
Fuzhou, FujianAges 18–65 - NCT06908382RecruitingPhase 2
Neoadjuvant QL1706 therapy for esophageal cancer before surgery
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Jinan, ShandongAges 18–75 - NCT07266480RecruitingPhase 2
Adalimumab after surgery for esophageal cancer
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT04328948RecruitingPhase 3
Preventive radiation for early esophagus cancer after chemoradiation
This Phase 3 trial tests whether giving preventive (prophylactic) radiation reduces cancer coming back in people with early esophagus cancer after standard chemoradiation. It may help by lowering the chance that microscopic cancer spreads to nearby areas.
TokyoAges 20 years+ - NCT04460352RecruitingPhase 3
Esophageal cancer treatment with chemoradiation plus planned surgery
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
Montreal, QuebecAges 18–80 - NCT04522687Recruiting
Blood lymphocyte changes studied during radiation and chemotherapy for lung cancers
This study looks at how a type of white blood cell in your blood changes while you receive radiation and chemotherapy. The goal is to see whether these blood changes relate to treatment, especially in certain chest (thoracic) cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04807673RecruitingPhase 3
Pembrolizumab before surgery versus chemoradiation for esophageal cancer
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07697859Recruiting
Immunotherapy with local treatment for limited spread esophageal cancer
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal carcinoma?
- Yes. Clin2 currently lists 244 recruiting esophageal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Esophageal Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
- Metastatic Esophageal Carcinoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Resectable Esophageal Squamous Cell Carcinoma
- Advanced Esophageal Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.